Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte precursor cell | 10 studies | 30% ± 16% | |
ciliated cell | 9 studies | 32% ± 11% | |
astrocyte | 8 studies | 26% ± 14% | |
glutamatergic neuron | 8 studies | 44% ± 20% | |
enteroendocrine cell | 8 studies | 73% ± 21% | |
GABAergic neuron | 7 studies | 44% ± 21% | |
neuron | 7 studies | 64% ± 23% | |
amacrine cell | 7 studies | 50% ± 27% | |
retinal ganglion cell | 7 studies | 74% ± 27% | |
epithelial cell of proximal tubule | 6 studies | 47% ± 16% | |
retina horizontal cell | 6 studies | 63% ± 24% | |
kidney loop of Henle epithelial cell | 5 studies | 47% ± 22% | |
retinal cone cell | 5 studies | 51% ± 24% | |
retinal rod cell | 5 studies | 36% ± 12% | |
epithelial cell | 5 studies | 38% ± 17% | |
pancreatic A cell | 4 studies | 88% ± 10% | |
type B pancreatic cell | 4 studies | 85% ± 13% | |
OFF-bipolar cell | 4 studies | 53% ± 31% | |
ON-bipolar cell | 4 studies | 53% ± 31% | |
GABAergic amacrine cell | 4 studies | 51% ± 20% | |
abnormal cell | 4 studies | 28% ± 8% | |
neuroendocrine cell | 4 studies | 92% ± 9% | |
interneuron | 4 studies | 46% ± 13% | |
pancreatic D cell | 3 studies | 92% ± 8% | |
endothelial cell | 3 studies | 28% ± 12% | |
kidney distal convoluted tubule epithelial cell | 3 studies | 46% ± 23% | |
retinal bipolar neuron | 3 studies | 53% ± 19% | |
glycinergic amacrine cell | 3 studies | 46% ± 11% | |
rod bipolar cell | 3 studies | 45% ± 19% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 17275.60 | 2632 / 2642 | 98% | 203.75 | 693 / 705 |
kidney | 96% | 5613.12 | 85 / 89 | 49% | 63.26 | 445 / 901 |
adrenal gland | 21% | 1151.31 | 53 / 258 | 79% | 881.98 | 181 / 230 |
pancreas | 33% | 865.66 | 108 / 328 | 63% | 215.74 | 113 / 178 |
ovary | 1% | 7.28 | 1 / 180 | 69% | 105.77 | 295 / 430 |
prostate | 13% | 272.30 | 33 / 245 | 46% | 24.91 | 229 / 502 |
thymus | 2% | 54.05 | 11 / 653 | 48% | 49.71 | 288 / 605 |
uterus | 21% | 494.26 | 36 / 170 | 24% | 34.48 | 110 / 459 |
stomach | 7% | 144.89 | 26 / 359 | 30% | 46.32 | 87 / 286 |
intestine | 12% | 214.02 | 114 / 966 | 19% | 34.22 | 98 / 527 |
lung | 0% | 2.34 | 1 / 578 | 29% | 25.03 | 332 / 1155 |
esophagus | 1% | 29.40 | 17 / 1445 | 26% | 69.38 | 48 / 183 |
bladder | 0% | 0 | 0 / 21 | 17% | 13.36 | 86 / 504 |
breast | 0% | 6.42 | 1 / 459 | 16% | 10.09 | 176 / 1118 |
skin | 2% | 55.12 | 44 / 1809 | 13% | 6.30 | 62 / 472 |
liver | 0% | 8.27 | 1 / 226 | 14% | 15.95 | 58 / 406 |
eye | 0% | 0 | 0 / 0 | 10% | 3.64 | 8 / 80 |
tonsil | 0% | 0 | 0 / 0 | 4% | 3.58 | 2 / 45 |
lymph node | 0% | 0 | 0 / 0 | 3% | 1.02 | 1 / 29 |
heart | 3% | 73.43 | 29 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 1% | 18.95 | 7 / 929 | 0% | 0 | 0 / 0 |
adipose | 0% | 6.57 | 2 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 0% | 12.75 | 2 / 1335 | 0% | 0 | 0 / 0 |
muscle | 0% | 1.66 | 1 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0016486 | Biological process | peptide hormone processing |
GO_0007218 | Biological process | neuropeptide signaling pathway |
GO_0009409 | Biological process | response to cold |
GO_0002021 | Biological process | response to dietary excess |
GO_0005802 | Cellular component | trans-Golgi network |
GO_0005615 | Cellular component | extracellular space |
GO_0030141 | Cellular component | secretory granule |
GO_0004866 | Molecular function | endopeptidase inhibitor activity |
GO_0004867 | Molecular function | serine-type endopeptidase inhibitor activity |
GO_0005102 | Molecular function | signaling receptor binding |
Gene name | PCSK1N |
Protein name | ProSAAS (Proprotein convertase subtilisin/kexin type 1 inhibitor) (Proprotein convertase 1 inhibitor) (pro-SAAS) [Cleaved into: KEP; Big SAAS (b-SAAS); Little SAAS (l-SAAS) (N-proSAAS); Big PEN-LEN (b-PEN-LEN) (SAAS CT(1-49)); PEN; Little LEN (l-LEN); Big LEN (b-LEN) (SAAS CT(25-40))] |
Synonyms | |
Description | FUNCTION: May function in the control of the neuroendocrine secretory pathway. Proposed be a specific endogenous inhibitor of PCSK1. ProSAAS and Big PEN-LEN, both containing the C-terminal inhibitory domain, but not the further processed peptides reduce PCSK1 activity in the endoplasmic reticulum and Golgi. It reduces the activity of the 84 kDa form but not the autocatalytically derived 66 kDa form of PCSK1. Subsequent processing of proSAAS may eliminate the inhibition. Slows down convertase-mediated processing of proopiomelanocortin and proenkephalin. May control the intracellular timing of PCSK1 rather than its total level of activity (By similarity). .; FUNCTION: [Big LEN]: Endogenous ligand for GPR171. Neuropeptide involved in the regulation of feeding. .; FUNCTION: [PEN]: Endogenous ligand for GPR171. Neuropeptide involved in the regulation of feeding. . |
Accessions | Q9UHG2 ENST00000218230.6 |